Literature DB >> 10890991

Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases.

A V Marzano1, E Berti, M Paulli, R Caputo.   

Abstract

BACKGROUND: Cytophagic histiocytic panniculitis (CHP) is a rare subtype of panniculitis that usually follows a fatal course, with a terminal hemophagocytic syndrome. Recent reports on a subset of peripheral T-cell lymphoma named subcutaneous panniculitis-like T-cell lymphoma (SPTL) raised the question about the relationship between these entities. OBSERVATIONS: We describe 7 patients in the study: 1 with fatal CHP, 4 with SPTL, and 2 with long-term CHP. The 5 patients with fatal CHP and SPTL died of complications of hemophagocytic syndrome, with a disease duration ranging from 8 to 74 months. The other 2 patients were still alive 6 and 41 years after disease onset. Immunohistochemical results proved that 2 of the SPTL cases were type alpha/beta and expressed the cytotoxic/suppressor antigen CD8, while the other 2 were type gamma/delta and were positive for the natural killer-associated antigen CD56. In these 4 cases, molecular biology studies by polymerase chain reaction detected T-cell receptor gamma gene rearrangement, indicating a clonal process. In contrast, in the 2 patients who had long-term CHP, the polymerase chain reaction results failed to disclose clonality. In the subject with fatal CHP, genotypic analysis was not performed.
CONCLUSION: Our observations suggest that CHP and SPTL may span a clinicopathologic spectrum in which there is a natural disease progression from CHP to SPTL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10890991     DOI: 10.1001/archderm.136.7.889

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  8 in total

Review 1.  Treatment of T-cell non-Hodgkin's lymphoma.

Authors:  Andrew M Evens; Ronald B Gartenhaus
Journal:  Curr Treat Options Oncol       Date:  2004-08

2.  Cytophagic histiocytic panniculitis with fatal haemophagocytic lymphohistiocytosis in a paediatric patient with perforin gene mutation.

Authors:  Rong-Long Chen; Yung-Hsiang Hsu; Ikuyo Ueda; Shinsaku Imashuku; Kengo Takeuchi; Benjamin Pang-hsien Tu; Shih-Sung Chuang
Journal:  J Clin Pathol       Date:  2007-06-29       Impact factor: 3.411

3.  Subcutaneous panniculitis-like T-cell lymphoma with breast involvement: functional and morphological imaging findings.

Authors:  N Schramm; T Pfluger; M F Reiser; F Berger
Journal:  Br J Radiol       Date:  2010-05       Impact factor: 3.039

4.  Usefulness of F-18 FDG PET/CT in subcutaneous panniculitis-like T cell lymphoma: disease extent and treatment response evaluation.

Authors:  Jin-Suk Kim; Young Jin Jeong; Myung-Hee Sohn; Hwan-Jeong Jeong; Seok Tae Lim; Dong Wook Kim; Jae-Yong Kwak; Chang-Yeol Yim
Journal:  Radiol Oncol       Date:  2012-11-09       Impact factor: 2.991

5.  Cytophagic histiocytic panniculitis: report of two cases.

Authors:  Jayasree Manoj; Feroze Kaliyadan; Manoj Unni; A D Dharmaratnam
Journal:  Indian J Dermatol       Date:  2011-05       Impact factor: 1.494

6.  Subcutaneous Panniculitis-Like T-Cell Lymphoma (SPTL) in a Child with Spontaneous Resolution.

Authors:  Achiléa L Bittencourt; Maria das Graças Silva Vieira; Eny Guimarães Carvalho; Celeste Cunha; Iguaracyra Araujo
Journal:  Case Rep Oncol Med       Date:  2011-11-24

7.  Cytophagic histiocytic panniculitis, hemophagocytic lymphohistiocytosis and undetermined autoimmune disorder: reconciling the puzzle.

Authors:  Claudia Pasqualini; Mauro Jorini; Ines Carloni; Mirella Giangiacomi; Valentina Cetica; Maurizio Aricò; Fernando Maria de Benedictis
Journal:  Ital J Pediatr       Date:  2014-02-13       Impact factor: 2.638

8.  Cyclosporine A as a Primary Treatment for Panniculitis-like T Cell Lymphoma: A Case with a Long-Term Remission.

Authors:  Won Sup Lee; Ji-Hyen Hwang; Moon Jin Kim; Se-Il Go; Anna Lee; Haa-Na Song; Min Jeong Lee; Myung Hee Kang; Hoon-Gu Kim; Jeong-Hee Lee
Journal:  Cancer Res Treat       Date:  2014-07-15       Impact factor: 4.679

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.